Skip to main content
SpringerLink
Log in
Book cover

The Kock Pouch pp 143–165Cite as

Management of de Novo Crohn’s Disease after Reconstructive Surgery with Continent Ileostomy in Ulcerative Colitis

  • Chapter
  • First Online:

  • 263 Accesses

Abstract

Pouchitis, i.e. de novo inflammation of the ileal pouch, is a common complication in patients with ileal pouch anal anastomosis (IPAA) or continent ileostomy (Kock pouch) following colectomy for Ulcerative Colitis. It has an endoscopic appearance resembling the colorectal inflammation of Ulcerative Colitis, and causes symptoms with increased stool frequency, urgency, abdominal cramps, mucous and/or bloody exudates, and fever. The cumulative incidence is increasing with time from ileostomy takedown and is reported to affect more than 50% of patients within 10 years. About 10% develop chronic antibiotic refractory pouchitis. Some patients with pouchitis develop an inflammation with a phenotype resembling Crohn’s disease, although they preoperatively had a clinical presentation, endoscopic features and histopathology data indicating they had Ulcerative Colitis, including reexamination of the pathology specimens. There is no agreed definition of de novo Crohn’s disease of the pouch, but it often includes a Crohn-like ulcerative inflammation, involvement of the pre-pouch afferent limb, and non-anastomotic complications with strictures or fistulas unrelated to surgery. Making a firm diagnosis of de novo Crohn’s disease of the pouch can be challenging since the distinction of de novo Crohn’s disease from chronic antibiotic resistant pouchitis or technical complications related to surgery is often difficult. Making an accurate diagnosis of Crohn of the pouch versus a postoperative complication is important for both decisions regarding medical management, and pouch excision versus reconstruction. Most patients diagnosed with Crohn’s disease will no longer be considered for pouch reconstructive surgery. There is very limited data on the medical management of de novo Crohn of pouches and the study quality is often poor. The management of de novo Crohn of the continent ileostomy is therefore mainly taken from management of IBD in general and Crohn’s disease in particular. A successful management is facilitated by cooperation in a multidisciplinary team with gastroenterologists and colorectal surgeons, closely involving the patient in therapeutic decisions with a person centered approach.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Bibliography

  1. Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg. 2000;24:851–6.

    Article  CAS  PubMed  Google Scholar 

  2. Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996;38:234–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Romanos J, Samarasekera DN, Stebbing JF, et al. Outcome of 200 restorative proctocolectomy operations: the John Radcliffe hospital experience. Br J Surg. 1997;84:814–8.

    Article  CAS  PubMed  Google Scholar 

  4. Svaninger G, Nordgren S, Oresland T, et al. Incidence and characteristics of pouchitis in the Kock continent ileostomy and the pelvic pouch. Scand J Gastroenterol. 1993;28:695–700.

    Article  CAS  PubMed  Google Scholar 

  5. Hahnloser D, Pemberton JH, Wolff BG, et al. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg. 2007;94:333–40.

    Article  CAS  PubMed  Google Scholar 

  6. Banasiewicz T, Marciniak R, Kaczmarek E, et al. The prognosis of clinical course and the analysis of the frequency of the inflammation and dysplasia in the intestinal J-pouch at the patients after restorative proctocolectomy due to FAP. Int Colorectal Dis. 2011;26:1197–203.

    Article  Google Scholar 

  7. Meagher AP, Farouk R, Dozois RR, et al. J-ileal pouch anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800–3.

    Article  CAS  PubMed  Google Scholar 

  8. Lovegrove RE, Tilney HS, Heriot AG, et al. A comparison of adverse events and functional outcomes after restorative protocolectomy for familial adenoma-Tous polyposis and ulcerative colitis. Dis Colon Rectum. 2006;49:1293–306.

    Article  PubMed  Google Scholar 

  9. Zaghiyan K, Kamiński JP, Barmparas G, Fleshner P. De novo Crohn’s disease after ileal pouch anal anastomosis for ulcerative colitis and inflammatory bowel disease unclassified: long-term follow-up of a prospective inflammatory bowel disease registry. Am Surg. 2016;82:977–81.

    PubMed  Google Scholar 

  10. Shen B. Crohn’s disease of the ileal pouch: reality, diagnosis, and management. Inflamm Bowel Dis. 2009;15:284–94.

    Article  PubMed  Google Scholar 

  11. Lennard-Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD study group. Eur J Gastroenterol Hepatol. 1997;9:353–9.

    Article  CAS  PubMed  Google Scholar 

  12. Shen B, Fazio VW, Remzi FH, et al. Risk factors for clinical phenotypes of Crohn’s disease of the pouch. Am J Gastroenterol. 2006;101:2760–8.

    Article  PubMed  Google Scholar 

  13. Wolf JM, Achkar J-P, Lashner BA, et al. Afferent limb ulcers predict Crohn’s disease in patients with ileal pouch-anal anastomosis. Gastroenterology. 2004;126:1686–91.

    Article  PubMed  Google Scholar 

  14. Shen B, Fazio VW, Remzi FH, et al. Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouchanal anastomoses. Am J Gastroenterol. 2005;100:93–101.

    Article  PubMed  Google Scholar 

  15. Deutsch AA, McLeod RS, Cullen J, Cohen Z. Results of the pelvic-pouch procedure in patients with Crohn’s disease. Dis Colon Rectum. 1991;34:475–7.

    Article  CAS  PubMed  Google Scholar 

  16. Grobler SP, Hosie KB, Keighley MR. Randomized trial of loop ileostomy in restorative proctocolectomy. Br J Surg. 1992;79:903–6.

    Article  CAS  PubMed  Google Scholar 

  17. Hyman NH, Fazio VW, Tuckson WB, Lavery IC. Consequences of ileal pouch-anal anastomosis for Crohn’s colitis. Dis Colon Rectum. 1991;34:653–7.

    Article  CAS  PubMed  Google Scholar 

  18. Shen B, Fazio VW, Remzi FH, et al. Clinical features and quality of life in patients with different phenotypes of Crohn’s disease of the ileal pouch. Dis Colon Rectum. 2007;50:1450–9.

    Article  PubMed  Google Scholar 

  19. Stein RB, Lichtenstein GR. Complications after ileal pouch-anal anastomosis. Semin Gastrointest Dis. 2000;11:2–9.

    CAS  PubMed  Google Scholar 

  20. Shen B, Fazio VW, Remzi FH, Lashner BA. Clinical approach to diseases of ileal pouch-anal anastomosis. Am J Gastroenterol. 2005;100:2796–807.

    Article  PubMed  Google Scholar 

  21. Lightner AL, Fletcher JG, Pemberton JH, et al. Crohn’s disease of the pouch: a true diagnosis or an oversubscribed diagnosis of exclusion? Dis Colon Rectum. 2017;60:1201–8.

    Article  PubMed  Google Scholar 

  22. Tekkis PP, Fazio VW, Remzi F, et al. Risk factors associated with ileal pouch-related fistula following restorative proctocolectomy. Br J Surg. 2005;92:1270–6.

    Article  CAS  PubMed  Google Scholar 

  23. Ferrante M, D’Haens G, Dewit O, et al. Efficacy of infliximab in refractory pouchitis and Crohn’s disease-related complications of the pouch: a Belgian case series. Inflamm Bowel Dis. 2010;16:243–9.

    Article  PubMed  Google Scholar 

  24. Bell AJ, Price AB, Forbes A, et al. Pre-pouch ileitis: a disease of the ileum in ulcerative colitis after restorative proctocolectomy. Color Dis. 2006;8:402–10.

    Article  CAS  Google Scholar 

  25. McLaughlin SD, Clark SK, Bell AJ, et al. Incidence and short-term implications of prepouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2009;52:879–83.

    Article  PubMed  Google Scholar 

  26. Samaan MA, de Jong D, Sahami S, et al. Incidence and severity of prepouch ileitis: a distinct disease entity or a manifestation of refractory pouchitis? Inflamm Bowel Dis. 2016;22:662–8.

    Article  PubMed  Google Scholar 

  27. Segal JP, McLaughlin SD, Faiz OD, Clark SK, Hart AL. Incidence and long-term implications of prepouch ileitis: an observational study. Dis Colon Rectum. 2018;23 [Epub ahead of print].

    Google Scholar 

  28. Fraquelli M, Colli A, Casazza G, et al. Role of US in detection of Crohn disease: meta-analysis. Radiology. 2005;236:95–101.

    Article  PubMed  Google Scholar 

  29. Koh DM, Miao Y, Chinn RJ, et al. MR imaging evaluation of the activity of Crohn’s disease. Am J Roentgenol. 2001;177:1325–32.

    Article  CAS  Google Scholar 

  30. Horsthuis K, Bipat S, Bennink RJ, et al. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology. 2008;247:64–79.

    Article  PubMed  Google Scholar 

  31. Panes J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34:125–45.

    Article  CAS  PubMed  Google Scholar 

  32. Qiu Y, Mao R, Chen BL, et al. Systematic review with meta-analysis: magnetic resonance enterography vs. computed tomography enterography for evaluating disease activity in small bowel Crohn’s disease. Aliment Pharmacol Ther. 2014;40:134–46.

    Article  CAS  PubMed  Google Scholar 

  33. Wold PB, Fletcher JG, Johnson CD, et al. Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study. Radiology. 2003;229:275–81.

    Article  PubMed  Google Scholar 

  34. Takenaka K, Ohtsuka K, Kitazume Y, Matsuoka K, Fujii T, Nagahori M, Kimura M, Fujioka T, Araki A, Watanabe M. Magnetic resonance evaluation for small bowel strictures in Crohn’s disease: comparison with balloon enteroscopy. J Gastroenterol. 2017;52:879–88.

    Article  PubMed  Google Scholar 

  35. Rispo A, Imperatore N, Testa A, et al. Bowel damage in Crohn’s disease: direct comparison of ultrasonography-based and magnetic resonance-based Lemann index. Inflamm Bowel Dis. 2017;23:143–51.

    Article  PubMed  Google Scholar 

  36. Tillack C, Seiderer J, Brand S, et al. Correlation of magnetic resonance enteroclysis (MRE) and wireless capsule endoscopy (CE) in the diagnosis of small bowel lesions in Crohn’s disease. Inflamm Bowel Dis. 2008;14:1219–28.

    Article  PubMed  Google Scholar 

  37. Geboes K, Colombel JF, Greenstein A, et al. Pathology task force of the International Organization of Inflammatory Bowel Diseases. Indeterminate colitis: a review of the concept--what’s in a name? Inflamm Bowel Dis. 2008;14:850–7.

    Article  PubMed  Google Scholar 

  38. Bernades P, Hecketsweiler P, Benozio M, et al. Proposal of a system of criteria for the diagnosis of cryptogenetic inflammatory enterocolitis (Crohn’s disease and hemorrhagic rectocolitis). A cooperative study by the cryptogenic enterocolitis study group. Gastroenterol Clin Biol. 1978;2:1047–54.

    CAS  PubMed  Google Scholar 

  39. Li Y, Wu B, Shen B. Diagnosis and differential diagnosis of Crohn’s disease of the ileal pouch. Curr Gastroenterol Rep. 2012;14:406–13.

    Article  CAS  PubMed  Google Scholar 

  40. Garrett KA, Remzi FH, Kirat HT, et al. Outcome of salvage surgery for ileal pouches referred with a diagnosis of Crohn’s disease. Dis Colon Rectum. 2009;52:1967–74.

    Article  PubMed  Google Scholar 

  41. Zundler S, Neurath MF. Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing. Clin Exp Rheumatol. 2015;33(4 Suppl 92):S19–28.

    PubMed  Google Scholar 

  42. Sachar DB, Walfish A. Inflammatory bowel disease: one or two diseases? Curr Gastroenterol Rep. 2013;15:298.

    Article  PubMed  Google Scholar 

  43. Louis E, Van Kemseke C, Reenaers C. Necessity of phenotypic classification of inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2011;(25 Suppl 1):S2–7.

    Article  Google Scholar 

  44. Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26:349–55.

    Article  PubMed  Google Scholar 

  45. Ellinghaus D, Bethune J, Petersen BS, et al. The genetics of Crohn’s disease and ulcerative colitis—status quo and beyond. Scand J Gastroenterol. 2015;50:13–23.

    Article  CAS  PubMed  Google Scholar 

  46. Bengtson MB, Solberg C, Aamodt G, et al. Clustering in time of familial IBD separates ulcerative colitis from Crohn’s disease. Inflamm Bowel Dis. 2009;15:1867–74.

    Article  PubMed  Google Scholar 

  47. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.

    Article  PubMed  Google Scholar 

  48. Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152:313–21.

    Article  PubMed  Google Scholar 

  49. Bridger S, Lee JC, Bjarnason I, et al. In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn’s disease and non-smokers develop ulcerative colitis. Gut. 2002;51:21–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11:1–10.

    Article  PubMed  Google Scholar 

  51. Theochari NA, Stefanopoulos A, Mylonas KS, Economopoulos KP. Antibiotics exposure and risk of inflammatory bowel disease: a systematic review. Scand J Gastroenterol. 2018;53:1–7.

    Article  CAS  PubMed  Google Scholar 

  52. Aniwan S, Tremaine WJ, Raffals LE, et al. Antibiotic use and new-onset inflammatory bowel disease in Olmsted county, Minnesota: a population-based case-control study. J Crohns Colitis. 2018;12:137–44.

    Article  PubMed  Google Scholar 

  53. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661–73.

    Article  CAS  PubMed  Google Scholar 

  54. Orel R, Kamhi TT. Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. World J Gastroenterol. 2014;20:11505–24.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Gomollón F, Dignass A, Annese V, et al. ECCO. 3rd European evidence-based consensus on the diagnosis and Management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25.

    Article  PubMed  Google Scholar 

  56. Lohmuller JL, Pemberton JH, Dozois RR, et al. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg. 1990;211:622–7. discussion 7–9

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Coffey JC, Rowan F, Burke J, et al. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am J Gastroenterol. 2009;104:1013–23.

    Article  PubMed  Google Scholar 

  58. Wu H, Shen B. Pouchitis and pouch dysfunction. Med Clin North Am. 2010;94:75–92.

    Article  CAS  PubMed  Google Scholar 

  59. Cheifetz A, Itzkowitz S. The diagnosis and treatment of pouchitis in inflammatory bowel disease. J Clin Gastroenterol. 2004;38:S44–50.

    Article  PubMed  Google Scholar 

  60. Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther. 1999;13:713–8.

    Article  CAS  PubMed  Google Scholar 

  61. Shen B, Fazio VW, Remzi FH, et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum. 2007;50:498–508.

    Article  PubMed  Google Scholar 

  62. Isaacs KL, Sandler RS, Abreu M, et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007;13:1250–5.

    Article  PubMed  Google Scholar 

  63. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci. 1994;39:1193–6.

    Article  CAS  PubMed  Google Scholar 

  64. Mimura T, Rizzello F, Helwig U, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther. 2002;16:909–17.

    Article  CAS  PubMed  Google Scholar 

  65. Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis. 2001;7:301–5.

    Article  CAS  PubMed  Google Scholar 

  66. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010;6:CD001176.

    Google Scholar 

  67. Gionchetti P, Amadini C, Rizzello F, et al. Probiotics for the treatment of postoperative complications following intestinal surgery. Best Pract Res Clin Gastroenterol. 2003;17:821–31.

    Article  PubMed  Google Scholar 

  68. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202–9.

    Article  PubMed  Google Scholar 

  69. Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther. 2005;22:721–8.

    Article  CAS  PubMed  Google Scholar 

  70. Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. 2007;50:2075–82.

    Article  PubMed  Google Scholar 

  71. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305–9.

    Article  CAS  PubMed  Google Scholar 

  72. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Lim M, Adams JD, Wilcox M, et al. An assessment of bacterial dysbiosis in pouchitis using terminal restriction fragment length polymorphisms of 16S ribosomal DNA from pouch effluent microbiota. Dis Colon Rectum. 2009;52:1492–500.

    Article  PubMed  Google Scholar 

  74. Sokol H, Lay C, Seksik P, et al. Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis. 2008;14:858–67.

    Article  PubMed  Google Scholar 

  75. Komanduri S, Gillevet PM, Sikaroodi M, et al. Dysbiosis in Pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol. 2007;5:352–60.

    Article  CAS  PubMed  Google Scholar 

  76. McLaughlin SD, Clark SK, Tekkis PP, et al. The bacterial pathogenesis and treatment of pouchitis. Therap Adv Gastroenterol. 2010;3:335–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Quinn KP, Lightner AL, Pendegraft RS, et al. Pouchitis is a common complication in patients with familial adenomatous polyposis following ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2016;14:1296–301.

    Article  PubMed  Google Scholar 

  78. Salemans JM, Nagengast FM, Lubbers EJ, Kuijpers JH. Postoperative and long-term results of ileal pouch-anal anastomosis for ulcerative colitis and familial polyposis coli. Dig Dis Sci. 1992;37:1882–9.

    Article  CAS  PubMed  Google Scholar 

  79. Shepherd NA, Healey CD, Warren BE, et al. Distribution ofmucosal pathology and anassessment ofcolonic phenotypic changein the pelvicheal reservoir. Gut. 1993;34:101–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Kmiot WA, Youngs D, Tudor R, et al. Mucosal morphology, cell proliferation and faecal bacteriology in acute pouchitis. Br J Surg. 1993;80:1445–9.

    Article  CAS  PubMed  Google Scholar 

  81. Duffy M, O’Mahony L, Coffey JC, et al. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis Colon Rectum. 2002;45:384–8.

    Article  CAS  PubMed  Google Scholar 

  82. Bath S, Selinger CP, Leong RWL. The pathogenesis of primary pouchitis following ileal pouch-anal anastomosis: a review of current hypotheses. J Gastroenterol. 2011;1:7–12.

    CAS  Google Scholar 

  83. Ruseler-Van Embden JG, Schouten WR, van Lieshout LM. Pouchitis: result of microbial imbalance? Gut. 1994;35:658–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Tannock GW, Lawley B, Munro K, et al. Comprehensive analysis of the bacterial content of stool from patients with chronic pouchitis, normal pouches, or familial adenomatous polyposis pouches. Inflamm Bowel Dis. 2012;18:925–34.

    Article  PubMed  Google Scholar 

  85. Bambury N, Coffey JC, Burke J, et al. Sulphomucin expression in ileal pouches: emerging differences between ulcerative colitis and familial adenomatous polyposis pouches. Dis Colon Rectum. 2008;51:561–7.

    Article  PubMed  Google Scholar 

  86. Fumery M, Dulai PS, Meirick P, et al. Systematic review with meta-analysis: recurrence of Crohn’s disease after total colectomy with permanent ileostomy. Aliment Pharmacol Ther. 2017;45:381–90.

    Article  CAS  PubMed  Google Scholar 

  87. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet. 1991;338:771–4.

    Article  CAS  PubMed  Google Scholar 

  88. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262–7.

    Article  CAS  PubMed  Google Scholar 

  89. Buisson A, Chevaux JB, Allen PB, et al. Review article: the natural history of postoperative Crohn’s disease recurrence. Aliment Pharmacol Ther. 2012;35:625–33.

    Article  CAS  PubMed  Google Scholar 

  90. Shamah S, Schneider J, Korelitz BI. High incidence of recurrent Crohn’s disease following colectomy for ulcerative colitis revealed with long follow-up. Dig Dis Sci. 2018;63:446–51.

    Article  PubMed  Google Scholar 

  91. Du P, Sun C, Ashburn J, et al. Risk factors for Crohn’s disease of the neo-small intestine in ulcerative colitis patients with total proctocolectomy and primary or secondary ileostomies. J Crohns Colitis. 2015;9:170–6.

    Article  PubMed  Google Scholar 

  92. Koriche D, Gower-Rousseau C, Chater C, et al. Post-operative recurrence of Crohn’s disease after definitive stoma: an underestimated risk. Int J Color Dis. 2017;32:453–8.

    Article  Google Scholar 

  93. Nessar G, Fazio VW, Tekkis P, et al. Long-term outcome and quality of life after continent ileostomy. Dis Colon Rectum. 2006;49:336–44.

    Article  PubMed  Google Scholar 

  94. Handelsman JC, Gottlieb LM, Hamilton SR. Crohn’s disease as a contraindication to Kock pouch (continent ileostomy). Dis Colon Rectum. 1993;36:840–3.

    Article  CAS  PubMed  Google Scholar 

  95. Brown CJ, Maclean AR, Cohen Z, et al. Crohn’s disease and indeterminate colitis and the ileal pouch-anal anastomosis: outcomes and patterns of failure. Dis Colon Rectum. 2005;48:1542–9.

    Article  PubMed  Google Scholar 

  96. Gemlo BT, Wong WD, Rothenberger DA, Goldberg SM. Ileal pouch-anal anastomosis. Patterns of failure. Arch Surg. 1992;127:784–7.

    Article  CAS  PubMed  Google Scholar 

  97. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomosis: complications and function in 1005 patients. Ann Surg. 1995;222:120–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Neilly P, Neill ME, Hill GL. Restorative proctocolectomy with ileal pouch-anal anastomosis in 203 patients: the Auckland experience. Aust NZ J Surg. 1999;69:22–7.

    Article  CAS  Google Scholar 

  99. Keighley MRB. The final diagnosis in pouch patients for presumed ulcerative colitis may change to Crohn’s disease: patients should be warned of the consequences. Acta Chir Ingoslav. 2000;47(suppl 4):27–31.

    CAS  Google Scholar 

  100. Yu CS, Pemberton JH, Larson D. Ileal pouch-anal anastomosis in patients with indeterminate colitis: long-term results. Dis Colon Rectum. 2000;43:1487–96.

    Article  CAS  PubMed  Google Scholar 

  101. Peyrègne V, Francois Y, Gilly FN, Descos JL, Flourie B, Vignal J. Outcome of ileal pouch after secondary diagnosis of Crohn’s disease. Int J Color Dis. 2000;15:49–53.

    Article  Google Scholar 

  102. Tulchinsky H, Hawley PR, Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg. 2003;238:229–34.

    PubMed  PubMed Central  Google Scholar 

  103. Hartley JE, Fazio VW, Remzi FH, et al. Analysis of the outcome of ileal pouch-anal anastomosis in patients with Crohn’s disease. Dis Colon Rectum. 2004;47:1808–15.

    Article  CAS  PubMed  Google Scholar 

  104. Murrell ZA, Melmed GY, Ippoliti A, et al. A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis. Dis Colon Rectum. 2009;52:872–8.

    Article  PubMed  Google Scholar 

  105. Delaney CP, Remzi FH, Gramlich T, et al. Equivalent function, quality of life and pouch survival rates after ileal pouch-anal anastomosis for indeterminate and ulcerative colitis. Ann Surg. 2002;236:43–8.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Melmed GY, Fleshner PR, Bardakcioglu O, et al. Family history and serology predict Crohn’s disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2008;51:100–8.

    Article  PubMed  Google Scholar 

  107. Shen B, Remzi FH, Hammel JP, et al. Family history of Crohn’s disease increases the risk for Crohn’s disease of ileal pouch-anal anastomosis. Inflamm Bowel Dis. 2009;15:163–70.

    Article  PubMed  Google Scholar 

  108. Stahlberg D, Gullberg K, Liljeqvist L, et al. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum. 1996;39:1012–8.

    Article  CAS  PubMed  Google Scholar 

  109. Hata K, Watanabe T, Shinozaki M, Nagawa H. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand J Gastroenterol. 2003;38:1055–8.

    Article  CAS  PubMed  Google Scholar 

  110. Wasmuth HH, Svinsås M, Tranø G, et al. Surgical load and long-term outcome for patients with Kock continent ileostomy. Color Dis. 2007;9:713–7.

    Article  CAS  Google Scholar 

  111. Köhler LW, Pemberton JH, Zinsmeister AR, Kelly KA. Quality of life after proctocolectomy. A comparison of Brooke ileostomy, Kock pouch, and ileal pouch-anal anastomosis. Gastroenterology. 1991;101:679–84.

    Article  PubMed  Google Scholar 

  112. Crawshaw A, Williams J, Woodhouse F. The Kock pouch reconsidered: an alternative surgical technique. Br J Nurs. 2014;23:S26–9.

    Article  PubMed  Google Scholar 

  113. Taleban S, Van Oijen MG, Vasiliauskas EA, et al. Colectomy with permanent end ileostomy is more cost-effective than ileal pouch-anal anastomosis for Crohn’s colitis. Dig Dis Sci. 2016;61:550–9.

    Article  PubMed  Google Scholar 

  114. Dehni N, Remacle G, Dozois RR, et al. Salvage reoperation for complications after ileal pouch-anal anastomosis. Br J Surg. 2005;92:748–53.

    Article  CAS  PubMed  Google Scholar 

  115. Baixauli J, Delaney CP, Wu JS, et al. Functional outcome and quality of life after repeat ileal pouchanal anastomosis for complications of ileoanal surgery. Dis Colon Rectum. 2004;47:2–11.

    Article  PubMed  Google Scholar 

  116. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138:463–8.

    Article  PubMed  Google Scholar 

  117. Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152:351–61.

    Article  PubMed  Google Scholar 

  118. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.

    Article  CAS  PubMed  Google Scholar 

  119. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371:660–7.

    Article  CAS  PubMed  Google Scholar 

  120. Colombel JF, Reinisch W, Mantzaris GJ, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn’s disease - a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015;41:734–46.

    Article  CAS  PubMed  Google Scholar 

  121. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.

    Article  CAS  PubMed  Google Scholar 

  122. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5–36.

    Article  Google Scholar 

  123. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Shen B, Remzi FH, Lavery IC, et al. A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2008;6:145–58.

    Article  PubMed  Google Scholar 

  125. Orscheln ES, Dillman JR, Towbin AJ, et al. Penetrating Crohn disease: does it occur in the absence of stricturing disease? Abdom Radiol (NY). 2017.; [Epub ahead of print]

    Google Scholar 

  126. Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Color Dis. 2005;7:182.

    Article  CAS  Google Scholar 

  127. Shen B, Remzi FH, Lopez AR, Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol. 2008;8:26.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  128. Kelly OB, Rosenberg M, Tyler AD, et al. Infliximab to treat refractory inflammation after pelvic pouch surgery for ulcerative colitis. J Crohns Colitis. 2016;10:410–7.

    Article  PubMed  Google Scholar 

  129. Huguet M, Pereira B, Goutte M, et al. Systematic review with meta-analysis: anti-TNF therapy in refractory pouchitis and Crohn’s disease-like complications of the pouch ffter ileal pouch-anal anastomosis following colectomy for ulcerative colitis. Inflamm Bowel Dis. 2018;24:261–8.

    Article  PubMed  Google Scholar 

  130. Bär F, Kühbacher T, Dietrich NA, et al. German IBD study group. Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis. Aliment Pharmacol Ther. 2018;47:581–7.

    Article  PubMed  CAS  Google Scholar 

  131. Verstockt B, Claeys C, Van Assche G, et al.. Vedolizumab can induce clinical remission in patients with chronic antibiotic-refractory pouchitis: A retrospective single-centre experience. The ECCO congress, Vienna 2018, abstract P624.

    Article  Google Scholar 

  132. Rezaie A, Kuenzig ME, Benchimol EI, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;6:CD000296.

    Google Scholar 

  133. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn’s disease. Canadian inflammatory bowel disease study group. N Engl J Med. 1994;331:836–41.

    Article  CAS  PubMed  Google Scholar 

  134. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–5.

    Article  CAS  PubMed  Google Scholar 

  135. Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The global budesonide study group. Gut. 1997;41:209–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli budesonide study group. Gastroenterology. 1998;115:835–40.

    Article  CAS  PubMed  Google Scholar 

  137. Benchimol EI, Seow CH, Steinhart AH, et al. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008:CD006792.

    Google Scholar 

  138. Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3:113–21.

    Article  CAS  PubMed  Google Scholar 

  139. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36.

    Article  PubMed  Google Scholar 

  141. Kuenzig ME, Rezaie A, Seow CH, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD002913.298.

    Google Scholar 

  142. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2003:CD000301.

    Google Scholar 

  143. Summers RW, Switz DM, Sessions JT, et al. National cooperative Crohn’s disease study: results of drug treatment. Gastroenterology. 1979;77:847–69.

    CAS  PubMed  Google Scholar 

  144. Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn’s disease study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249–66.

    CAS  PubMed  Google Scholar 

  145. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35:360–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.

    Article  CAS  PubMed  Google Scholar 

  147. Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319–30.

    Article  CAS  PubMed  Google Scholar 

  148. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390:2779–89.

    Article  Google Scholar 

  149. Colombel JF, Reinisch W, Mantzaris GJ, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn’s disease - a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015;41:734–46.

    Article  CAS  PubMed  Google Scholar 

  150. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981–7.

    Article  CAS  PubMed  Google Scholar 

  151. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2010;6:CD000545.

    Google Scholar 

  152. Chande N, Townsend CM, Parker CE, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2016;10:CD000545.

    PubMed  Google Scholar 

  153. Chande N, Patton PH, Tsoulis DJ, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;10:CD000067.

    Google Scholar 

  154. de Boer NKH, Peyrin-Biroulet L, Jharap B, et al. Thiopurines in inflammatory bowel disease: new findings and perspectives. J Crohns Colitis. 2017. [Epub ahead of print].

    Google Scholar 

  155. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63–70.

    Article  CAS  PubMed  Google Scholar 

  156. Van Asseldonk DP, de Boer NK, Peters GJ, et al. On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance. Curr Drug Metab. 2009;10:981–97.

    Article  PubMed  Google Scholar 

  157. Jharap B, Seinen ML, de Boer NK, et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis. 2010;16:1541–9.

    Article  CAS  PubMed  Google Scholar 

  158. Coenen MJ, de Jong DJ, van Marrewijk CJ, et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology. 2015;149:907–17.

    Article  PubMed  Google Scholar 

  159. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705–13.

    Article  CAS  PubMed  Google Scholar 

  160. Yarur AJ, Gondal B, Hirsch A, et al. Higher thioguanine nucleotide metabolite levels are associated with better long-term outcomes in patients with inflammatory bowel diseases. J Clin Gastroenterol. 2017. [Epub ahead of print].

    Google Scholar 

  161. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904–15.

    Article  CAS  PubMed  Google Scholar 

  162. Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:640–7.

    Article  CAS  PubMed  Google Scholar 

  163. Sparrow MP. Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2008;4:505–11.

    Google Scholar 

  164. Nagy F, Molnar T, Szepes Z, et al. Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. World J Gastroenterol. 2008;14:4342–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Bermejo F, Lopez-Sanroman A, Algaba A, et al. Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:120–4.

    Article  CAS  PubMed  Google Scholar 

  166. Herfarth HH, Kappelman MD, Long MD, et al. Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22:224–33.

    Article  PubMed  Google Scholar 

  167. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The north American Crohn’s study group investigators. N Engl J Med. 1995;332:292–7.

    Article  CAS  PubMed  Google Scholar 

  168. McDonald JW, Wang Y, Tsoulis DJ, et al. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD003459.

    Google Scholar 

  169. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s study group investigators. N Engl J Med. 2000;342:1627–32.

    Article  CAS  PubMed  Google Scholar 

  170. Patel V, Wang Y, MacDonald JK, et al. Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD006884.

    Google Scholar 

  171. Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn’s disease. Aliment Pharmacol Ther. 2003;18:57–63.

    Article  CAS  PubMed  Google Scholar 

  172. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010;59:1363–8.

    Article  CAS  PubMed  Google Scholar 

  173. Yarur AJ, Kubiliun MJ, Czul F, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015;13:1118–24.

    Article  CAS  PubMed  Google Scholar 

  174. Roblin X, Boschetti G, Williet N, et al. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther. 2017;46:142–9.

    Article  CAS  PubMed  Google Scholar 

  175. Ungar B, Kopylov U, Engel T, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther. 2017;45:276–82.

    Article  CAS  PubMed  Google Scholar 

  176. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:444–7.

    Article  CAS  PubMed  Google Scholar 

  177. Bots S, Gecse K, Barclay M, D'Haens G. Combination Immunosuppression in IBD. Inflamm Bowel Dis. 2018;24:539–45.

    Article  PubMed  Google Scholar 

  178. Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  179. Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:1293–301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  180. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.

    Article  CAS  PubMed  Google Scholar 

  181. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618–27.

    Article  CAS  PubMed  Google Scholar 

  182. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130–41.

    Article  CAS  PubMed  Google Scholar 

  183. Yarur AJ, Rubin DT. Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:1709–18.

    Article  PubMed  Google Scholar 

  184. Ben-Horin S. Drug level-based anti-tumor necrosis factor therapy: ready for prime time? Gastroenterology. 2015;148:1268–71.

    Article  PubMed  Google Scholar 

  185. Mitrev N, Leong RW. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease. Expert Opin Drug Saf. 2017;16:303–17.

    Article  CAS  PubMed  Google Scholar 

  186. Hassan C, Zullo A, De Francesco V, et al. Systematic review: endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther. 2007;26:1457–64.

    Article  CAS  PubMed  Google Scholar 

  187. Shen B, Fazio VW, Remzi FH, et al. Endoscopic balloon dilation of ileal pouch strictures. Am J Gastroenterol. 2004;99:2340–7.

    Article  PubMed  Google Scholar 

  188. Reese GE, Purkayastha S, Tilney HS, et al. Strictureplasty vs resection in small bowel Crohn’s disease: an evaluation of short-term outcomes and recurrence. Color Dis. 2007;9:686–94.

    Article  CAS  Google Scholar 

  189. Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for crohn’s disease: a systematic review and meta-analysis. Dis Colon Rectum. 2007;50:1968–86.

    Article  PubMed  Google Scholar 

  190. Fearnhead NS, Chowdhury R, Box B, et al. Long-term follow-up of strictureplasty for Crohn’s disease. Br J Surg. 2006;93:475–82.

    Article  CAS  PubMed  Google Scholar 

  191. Matzke GM, Kang AS, Dozois EJ, et al. Mid pouch stricturoplasty for Crohn’s disease after ileal pouch-anal anastomosis: an alternative to pouch excision. Dis Colon Rectum. 2004;47:782–6.

    Article  PubMed  Google Scholar 

  192. Wu XR, Mukewar S, Kiran RP, et al. Surgical stricturoplasty in the treatment of ileal pouch strictures. J Gastrointest Surg. 2013;17:1452–61.

    Article  PubMed  Google Scholar 

  193. Sagar PM, Dozois RR, Wolff BG. Long-term results of ileal pouch-anal anastomosis in patients with Crohn’s disease. Dis Colon Rectum. 1996;39:893–8.

    Article  CAS  PubMed  Google Scholar 

  194. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–405.

    Article  CAS  PubMed  Google Scholar 

  195. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–85.

    Article  CAS  PubMed  Google Scholar 

  196. Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol. 2004;2:912–20.

    Article  CAS  PubMed  Google Scholar 

  197. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58:940–8.

    Article  CAS  PubMed  Google Scholar 

  198. Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63:1381–92.

    Article  PubMed  Google Scholar 

  199. Molendijk I, Peeters KC, Baeten CI, et al. Improving the outcome of fistulising Crohn’s disease. Best Pract Res Clin Gastroenterol. 2014;28:505–18.

    Article  PubMed  Google Scholar 

  200. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132–42.

    Article  CAS  PubMed  Google Scholar 

  201. Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and Management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2017;11:135–49.

    Article  PubMed  Google Scholar 

  202. West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329–36.

    Article  CAS  PubMed  Google Scholar 

  203. Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63:292–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden

    Henrik Hjortswang

Authors
  1. Henrik Hjortswang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Henrik Hjortswang .

Editor information

Editors and Affiliations

  1. Linköping University Hospital, Department of Surgery, Linköping University, Department of Clinical and Experimental Medicine, Linköping, Sweden

    Pär Myrelid

  2. Department of Surgery, Colorectal Unit, Sahlgrenska University Hospital, Östra, Göteborg, Sweden

    Mattias Block

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hjortswang, H. (2019). Management of de Novo Crohn’s Disease after Reconstructive Surgery with Continent Ileostomy in Ulcerative Colitis. In: Myrelid, P., Block, M. (eds) The Kock Pouch. Springer, Cham. https://doi.org/10.1007/978-3-319-95591-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-95591-9_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-95590-2

  • Online ISBN: 978-3-319-95591-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation